Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Liver is the largest solid organ in the body that performs over 100 functions. It removes the
toxins and waste products from the blood stream, maintains healthy blood sugar levels …

Background & Aims The tumour microenvironment (TME) is a crucial mediator of cancer
progression and therapeutic outcome. The TME subtype correlates with patient response to …

The liver is the sixth most common site of primary cancer in humans, and generally arises in
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Hepatocellular carcinoma (HCC) can have viral or non-viral causes,,,–. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …

PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–
associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand …

Importance Most patients with hepatocellular carcinoma (HCC) are diagnosed with
advanced disease not eligible for potentially curative therapies; therefore, new treatment …

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …